|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Disagreement between symptom-reflux association analysis parameters in pediatric gastroesophageal reflux disease investigation显示文摘AIM: To assess the agreement within 3 commonly used symptom-reflux association analysis (SAA) parameters investigating gastroesophageal reflux disease (GERD) in infants. METHODS: Twenty three infants with suspected GERD were included in this study. Symptom index (SI), Symptom sensitivity index (SSI) and symptom association probability (SAP) related to cough and irritability were calculated after 24 h combined pH/multiple intraluminal impedance (MII) monitoring. Through defined cutoff values, SI, SSI and SAP values are differentiated in normal and abnormal, whereas abnormal values point towards gastroesophageal reflux (GER) as the origin of symptoms. We analyzed the correlation and the concordance of the diagnostic classification of these 3 SAA parameters.RESULTS: Evaluating the GER-irritability association, SI, SSI and SAP showed non-identical classification of normal and abnormal cases in 39.2% of the infants. When irritability was taken as a symptom, there was only a poor inter-parameter association between SI and SSI, and between SI and SAP (Kendall’s tau b = 0.37, P < 0.05; Kendall’s tau b = 0.36, P < 0.05, respectively). Evaluating the GER-cough association, SI, SSI and SAP showed non-identical classification of normal and abnormal cases in 52.2% of the patients. When cough was taken as a symptom, only SI and SSI showed a poor inter-parameter association (Kendall’s tau b = 0.33, P < 0.05). CONCLUSION: In infants investigated for suspected GERD with pH/MII-monitoring, SI, SSI and SAP showed a poor inter-parameter association and important dis-agreements in diagnostic classification. These limitations must be taken into consideration when interpreting the results of SAA in infants. | Samuel C Lüthold Mascha K Rochat Peter Bhler | 2010 | World Journal of Gastroenterology2010，16，19： | 3 |
| 2 | Human CYP1B1 and anticancer agent metabolism:mechanism for tumor-specific drug inactivation显示文摘 | Rochat B Morsman J M Murray G I | 2001 | J Pharmacol Exp Ther2001，296，2： | 1 |
| 3 | Effect of RasGAP N2 gragment-derived peptide on tumor growth in mice 显示文摘 | Michod D Annibaldi A Schaefer S Dapples C Rochat B Widmann C | 2009 | J Natl Cancer Inst2009，101，11： | 1 |
| 4 | Fragmentation study of imatinib and char acterization of new imatinib metabolites by liquid chromatogra- phy-triple-quadrupole and linear ion trap mass spectrometers显示文摘 | Marull M Rochat B | 2006 | J Mass Spectrom2006，41，3： | 1 |
| 5 | Human CYP1B1 and anticancer agent metabolism :mechanism for tumor-specific drug inactivation显示文摘 | ROCHAT B MORSMAN J M MURRAY G I | 2001 | JPharmacol Exp Ther2001，296，2： | 1 |
| 6 | Storage reserve accumulation in Arabidop- sis 显示文摘 | Baud S Dubreucq B Miquel M Rochat C Lepi- niec L | 2008 | Plant Cell2008，34，5： | 1 |
| 7 | Cy-mag3D: A simple and miniature climbing robot with advance mobility in ferromagnetic environment显示文摘 | Rochat F Schoeneich P Luthi B | 2011 | Industrial Robot2011，38，3： | 1 |
| 8 | Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism 显示文摘 | Rochat B | 2005 | Clin Phannacokinet2005，44，4： | 1 |
| 9 | Quantitative performance of a quadrupole-orbitrap-MS in targeted LC-MS determinations of small molecules显示文摘 | GRUND B MARVIN L ROCHAT B | 2016 | J Pharm Biomed Anal2016，124，5： | 1 |
| 10 | Determination Of lmatinib (Gleevec ) In Human Plasma By Solid-Phase Extraction-Liquid Chromatography-Ultraviolet Absorbance Detection 显示文摘 | Widmer N Beguin A Rochat B | 2004 | Journal of Chromatography2004，803，： | 1 |
| 11 | In vitro biotransformation of imatinib by the tumor expressed CYP1A1 and CYP1B1 显示文摘 | Rochat B Zoete V Grosdidier A | 2008 | Biopharm Drug Dispos2008，29，： | 1 |
| 12 | Therapeutic drug monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitini-b, sorafenib and lapatinib by LC tandem mass spectrometry 显示文摘 | Hauoala A Zanolari B Rochat B | 2009 | J Chromatogr B Analyt Technol Biomed Life Sci2009，877，22： | 1 |
| 13 | Human CYP1B1 and anticancer agent metabolism:mechanism for tumor-specific drug inactivation?显示文摘 | Rochat B Morsman J M Murray G I | 2001 | J Pharmacol Exp Ther2001，296，2： | 1 |
| 14 | Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes显示文摘 | Rochat B Amey M Gillet M | | Pharmacogenetics0，7，1： | 1 |
| 15 | Heel and Toe Clearance Estimation for Gait Analysis Using Wireless Inertial Sensors显示文摘 | Mariani B Rochat S Bula C J | 2012 | IEEE Trans Biomed Eng2012，59，11： | 1 |
| 16 | 3D gait assessment in young and elderly subjects using foot-worn inertial sensors显示文摘 | Benoit Mariani Constanze Hoskovec Stephane Rochat Christophe Büla Julien Penders Kamiar Aminian | 2010 | Journal of Biomechanics2010，，： | 1 |
| 17 | Transport mechanisms for the antidepressant RS-citalopram in brain microvessel endothelium显示文摘 | ROCHAT B BAUMANN P AUDUS KL | 1999 | Brain Res1999，831，12： | 1 |
| 18 | Ultra-performance liquid chromatography mass spectrometry and sensitive bioassay methods for quantification of posaconazole plasma concentrations after oral dosing显示文摘 | Rochat B Pascual A Pesse B | 2010 | Antimicrob Agents Chemother2010，54，12： | 1 |
| 19 | Analysis of enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography显示文摘 | ROCHAT B AMEY M BAUMANN P | 1995 | Ther Drug Monit1995，17，3： | 1 |
| 20 | Determination of the enantiomers of citalopram,its demethylated and propionic acid metabolites in human plasma by chiral HPLC显示文摘 | Rochat B Amey M van Gelderen H | 1995 | Chirality1995，7，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员